News
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced updated data from its ongoing Phase 2…
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today…
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of…
This seminar will provide information on the treatment and management of ATTR amyloidosis, as well as a discussion of future directions for research and treatment.…
The first team to disable a disease gene directly in a person through an infusion of the genome editor CRISPR reported yesterday that levels of the toxic protein…
Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome…
This program is intended for people interested in learning about hATTR amyloidosis, including individuals diagnosed with hATTR amyloidosis, their families, and…
This program is intended for people interested in learning about hATTR amyloidosis, including individuals diagnosed with hATTR amyloidosis, their families, and…
How may carpal tunnel syndrome, numbness in hands or feet, shortness of breath, dizziness, and diarrhea be related to each other? These symptoms could be caused by…
Please join us on March 19th, 2022 from 12:30 PM - 3:30 PM ET for our next webinar on ATTRv and ATTRwt Amyloidosis. Our speakers include Cardiologists,…